Mixed Q2 for Humana: Earnings Beat and Cost Control, but No Guidance Raise Sparks Selloff
Humana posts $7.61 adjusted EPS, topping estimates as costs remain in line; shares decline after full-year guidance is reaffirmed without an increase.
/ 10 items
#HUM↓
Strong Medicare Outlook Drives Wells Fargo’s Bullish Upgrade on Humana
Analyst highlights improving Medicare margins and star ratings for stronger 2028 earnings.
Humana Beats Q1 2026 Earnings Expectations, Reaffirms Full-Year Adjusted Profit Guidance
Humana beat Q1 2026 expectations, revenue rose, Medicare membership grew, outlook steady but GAAP cut due to lower ratings.
Insurer Stocks Soar After CMS Finalizes 2027 Medicare Payments
CMS boosts 2027 Medicare payments 2.5%, giving insurers $13B+, keeping plans stable and seniors’ benefits solid. Stocks jump.
Humana's 2026 Profit Forecast Falls Short of Expectations
Humana predicts lower 2026 profits due to reduced Medicare ratings, projecting at least $9 per share against Wall Street's $11.92 estimate amid market challenges.
Morgan Stanley Cuts Humana Rating Amid Medicare Advantage Concerns
Morgan Stanley downgraded Humana to Underweight, citing policy risks and disappointing Medicare Advantage updates, with a new price target of $174.